Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment
Pharmaceuticals · 19.04.2024 · 17 (4) · 530
DOI: 10.3390/ph17040530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 19.04.2024. Verfasst von Gabriela Dumitrita Stanciu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu"-CEMEX, Grigore T. Popa University of Medicine and Pharmacy…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by a grant from the Ministry of Research, Innovation and Digitaliza-tion, CNCS-UEFISCDI, Ministry of Research, Innovation and Digitalization, CNCS-UEFISCDI, Romanian National Authority for Scientific Research and Innovation, CCCDI-UEFISCDI.
Themen: Demenz
Abstract (Originalsprache)
Despite decades of rigorous research and numerous clinical trials, Alzheimer’s disease (AD) stands as a notable healthcare challenge of this century, with effective therapeutic solutions remaining elusive. Recently, the endocannabinoid system (ECS) has emerged as an essential therapeutic target due to its regulatory role in different physiological processes, such as neuroprotection, modulation of inflammation, and synaptic plasticity. This aligns with previous research showing that cannabinoid receptor ligands have the potential to trigger the functional structure of neuronal and brain networks, potentially impacting memory processing. Therefore, our study aims to assess the effects of prolonged, intermittent exposure (over 90 days) to JWH-133 (0.2 mg/kg) and an EU-GMP certified Cannabis sativa L. (Cannabixir® Medium Flos, 2.5 mg/kg) on recognition memory, as well as their influence on brain metabolism and modulation of the expanded endocannabinoid system in APP/PS1 mice. Chronic therapy with cannabinoid receptor ligands resulted in reduced anxiety-like behavior and partially reversed the cognitive deficits. Additionally, a reduction was observed in both the number and size of Aβ plaque deposits, along with decreased cerebral glucose metabolism, as well as a decline in the expression of mTOR and CB2 receptors. Furthermore, the study revealed enlarged astrocytes and enhanced expression of M1 mAChR in mice subjected to cannabinoid treatment. Our findings highlight the pivotal involvement of the extended endocannabinoid system in cognitive decline and pathological aspects associated with AD, presenting essential preclinical evidence to support the continued exploration and assessment of cannabinoid receptor ligands for AD treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu"-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
- Pharmacodynamics and Clinical Pharmacy Department, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
- Faculty of Veterinary Medicine, "Ion Ionescu de la Brad" University of Life Sciences, 700490 Iasi, Romania.
- Department of Computer Science, "Alexandru Ioan Cuza" University of Iasi, 700506 Iasi, Romania.
- Department of Pharmacology, Clinical Pharmacology and Algesiology, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
ORCID-Profile: Gabriela Dumitrita Stanciu, Daniela-Carmen Ababei, Carmen Solcan, Cristina-Mariana Uritu, Vlad-Constantin Craciun, Cosmin-Vasilica Pricope, Andrei Szilagyi, Bogdan-Ionel Tamba
Förderung
- This work was supported by a grant from the Ministry of Research, Innovation and Digitaliza-tion, CNCS-UEFISCDI
- Ministry of Research, Innovation and Digitalization, CNCS-UEFISCDI
- Romanian National Authority for Scientific Research and Innovation, CCCDI-UEFISCDI
Zitieren
APA
Stanciu, G. D., Ababei, D. C., Solcan, C., Uritu, C. M., Craciun, V. C., Pricope, C. V., Szilagyi, A., & Tamba, B. I. (2024). Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment. Pharmaceuticals, 17(4), 530. https://doi.org/10.3390/ph17040530
Vancouver
Stanciu GD, Ababei DC, Solcan C, Uritu CM, Craciun VC, Pricope CV, et al. Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment. Pharmaceuticals. 2024;17(4):530. doi:10.3390/ph17040530
BibTeX
@article{Stanciu2024,
author = {Stanciu, Gabriela Dumitrita and Ababei, Daniela-Carmen and Solcan, Carmen and Uritu, Cristina-Mariana and Craciun, Vlad-Constantin and Pricope, Cosmin-Vasilica and Szilagyi, Andrei and Tamba, Bogdan-Ionel},
title = {Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {4},
pages = {530},
doi = {10.3390/ph17040530}
}
EUVIMED